Delivery Order SPE2DB20D1004-SPE2DB24FF1C5

Award Date 12/26/23
Potential Completion Date 12/27/23
Potential Value $4K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,863.33, is for the delivery of Xeljanz XR 11 mg tablets. It is a firm fixed-price delivery order contract with a completion date of September 20, 2023. This contract award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at $999,999,999 and running through...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Xeljanz XR 11 mg tablets. The contract is a firm-fixed price delivery order with a ceiling value of $15,817.74 and a completion date of November 18, 2024. The award is not associated with any set-aside program. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $29,823.95, is for the delivery of the specialty medication Xeljanz XR 11 mg tablets. The contract is a firm-fixed-price Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999, which serves as a primary vehicle for providing a comprehensive range of...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 MG TABLET, a prescription medication. The firm-fixed-price delivery order, valued at $22,912.52, has an ultimate completion date of August 22, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued up to $999,999,999 through December...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 MG TABLET. The award has a firm fixed price ceiling value of $5,901.13 and an ultimate completion date of August 30, 2024. This delivery order is placed under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of XELJANZ XR 11 MG TABLET 30S. The $9,755.10 firm-fixed-price delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has an ultimate completion date of November 16,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 MG TABLET 30S. The $7,896.21 firm fixed-price contract has a completion date of September 12, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the provision of a comprehensive range of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,399.29, is for the supply of Xeljanz 5 mg tablets to support federal healthcare programs. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a $14,590.47 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of XELJANZ XR 11 MG tablets and has an ultimate completion date of April 2, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $23,759.70 firm fixed-price contract is for the supply of XELJANZ XR 11 MG tablets. The contract has an ultimate completion date of April 15, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through...
  • SPE2DB20D1004
    Indefinite Delivery Contract
  • SPE2DB20D1004-SPE2DB24FF1C5
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Xeljanz XR 11 mg tablets. The $3,977.76 firm-fixed-price contract has a completion date of December 27, 2023 and was awarded on December 26, 2022. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC enables the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, and other critical healthcare commodities to support military treatment facilities and veteran healthcare programs worldwide. The contract award was made through full and open competition without any set-aside designation.

Generated 2/27/25, 10:36 AM